Analysts think VCYT stock price could increase by 59%
Jul 06, 2025, 11:25 AM
-0.04%
What does VCYT do
Veracyte, headquartered in South San Francisco, develops diagnostic products for various cancers and employs 815 people. The company went public in 2013 and offers tests like Afirma and Decipher.
12 analysts think VCYT stock price will increase by 59.43%. The current median analyst target is $43.86 compared to a current stock price of $27.51. The lowest analysts target is $29.29 and the highest analyst target is $53.55.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
